Xavier Becerra, President Joe Biden’s outgoing Health and Human Services secretary, is lamenting Americans’ abysmal distrust in federal health agencies while

BECERRA’S FINAL ACT — During the unveiling of his official portrait on Tuesday, HHS Secretary Xavier Becerra, who will soon depart the agency, highlighted the record number of people who have signed up for health insurance since he took the helm of the sprawling agency — and President Joe Biden’s role in it, Chelsea reports.

The Biden administration unveiled its list of 15 drugs, which include GLP-1 drugs, for the second annual round of drug price negotiations, made possible through the Inflation Reduction Act (IRA).

The Biden administration said a record 24.2 million Americans enrolled in individual coverage under the Affordable Care Act also known as Obamacare.

Xavier Becerra and his allies had a plan to restore Americans’ faith in the nation’s beleaguered public health agencies. Becerra, tapped by President Joe Biden to lead the Department of Health ...

The price negotiations for the additional 15 drugs selected will be handled by the incoming Trump administration and, if deals are reached, almost assure billions of dollars in savings for taxpayers.

The Centers for Medicare and Medicaid Services (CMS) has selected 15 more drugs for Medicare price negotiation, announcing the selection two weeks ahead of schedule.

Biden's administration announced weight loss drugs Ozempic and Wegovy will be included on Medicare's list of medications subject to direct price negotiations.

Becerra’s unwavering support for the Affordable Care Act helped land him the top job at the DHS, running a $1.7 trillion agency, developing vaccines and inspecting foods on supermarket shelves.

In a wide-ranging interview, Xavier Becerra, President Biden’s health secretary, defended his tenure and hinted that he might run for governor of California.

President-elect Donald Trump will likely travel to California next week to view the aftermath of the devastating wildfires in greater Los Angeles.

US health officials announced Friday they were awarding $590 million to Moderna to develop mRNA vaccines against influenza, including advancing the company's bird flu vaccine, as fears of a new pandemic grow.